Form 4: PTC Therapeutics EVP Lee Scott Golden Reports Stock Sale to Cover Tax Obligations
SEC Form 4
Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold 175 shares of common stock on May 7, 2024, to cover tax obligations related to vesting RSUs.
Summary
- On May 7, 2024, Lee Scott Golden, the EVP & Chief Medical Officer of PTC Therapeutics, sold 175 shares of the company's common stock.
- The sale was executed at a price of $32.82 per share.
- This transaction was conducted to cover tax withholding obligations associated with the vesting of 713 Restricted Stock Units (RSUs) from a grant made on May 11, 2020.
- Following the transaction, Golden directly owns 59,813 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine transaction to cover tax obligations, so it's neutral in sentiment.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This transaction is a common practice to cover tax obligations related to equity compensation.
Stakeholder Impact
- The transaction has minimal impact on stakeholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/11/2020 | Date of original grant of 2,850 RSUs, of which 713 vested. |
| 05/07/2024 | Date of the stock sale transaction. |
| 05/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.